Briacell Therapeutics Corp BCTX

$4.28 +0.27 (6.73%)

Valuation

Market cap
34,886,000
Revenue TTM
$0
Net income TTM
$-26,310,000
PE ratio
0.00
Forward PE
—
Profit margin
0.00%
Debt to equity
0.00

Trading

Volume
241,700
Avg volume
317,684
Day's range
$3.99 – $4.43
Shares out
8,700,000
Stochastic %K
84%
Beta
1.10
Analysts
Strong Buy
Price target
$40.00

Price

Company profile

BriaCell Therapeutics Corp., a pre-clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted immunotherapy program against end-stage breast cancer that is in Phase 3 clinical trials. The company develops Bria-OTS, a personalized off-the-shelf immunotherapy; and a soluble CD80 protein therapeutic that acts as a stimulator...

Show more

BriaCell Therapeutics Corp., a pre-clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted immunotherapy program against end-stage breast cancer that is in Phase 3 clinical trials. The company develops Bria-OTS, a personalized off-the-shelf immunotherapy; and a soluble CD80 protein therapeutic that acts as a stimulator of the immune system and an immune checkpoint inhibitor. It has a license agreement with the University of Maryland, Baltimore County to develop and commercialize soluble CD80 as a biologic agent for the treatment of cancer. BriaCell Therapeutics Corp., has a collaboration with MSK Accelerator to accelerate the clinical development of Bria-OTS+ for multiple cancer indications including metastatic breast cancer, prostate cancer, and other cancers. The company is headquartered in West Vancouver, Canada.

Industry
Biotechnology
Sector
Healthcare
Phone
604 921 1810
Website
https://briacell.com
Address
Bellevue Centre, Suite 300 235 -15th Street, West Vancouver, Canada

Latest news

Stocktwits

mostlyzero Sep 24, 7:40 PM
$BCTX $SLS getting some very thought provoking replies! Love the community feel here! 🥰 lol
1 replies
ZacksResearch Sep 24, 6:42 PM
$BCTX Gains 10.8% in a Month – Will the Momentum Continue? BriaCell’s pivotal Phase 3 Bria-ABC study continues without modifications after the DSMB raised no safety or other clinical concerns. The trial is being conducted under FDA Fast Track designation for metastatic breast cancer. What today’s news means for BCTX investors 👉 https://www.zacks.com/stock/quote/BCTX/detailed-earning-estimates?cid=sm-stocktwits-0-detailed_estimates-oc-39704&ADID=SYND_STOCKTWITS_TWEET_0_DETAILEDESTIMATES_OC_39704
0 replies
mostlyzero Sep 24, 6:24 PM
$BCTX those who’ve been here longer than I have tell me why this can’t become $SLS 2.0? The event driven nature of the trading thesis seems very similar. Strong signal from phase 2. Well designed phase 3. Low float. Not saying the risk profiles are analogous but… SLS: DSMC has already seen unblinded Phase 3 efficacy/futility data and said continue. BCTX: DSMB has repeatedly reviewed Phase 3 safety and said continue, while efficacy remains blinded until the 144-event analysis. I get that early investors have been burned here. But for those of us looking to add now? Beyond murky financing and dilution history, what am I missing from a bear lens?
4 replies
BHWinehouse Sep 24, 6:24 PM
$BCTX
0 replies
mostlyzero Sep 24, 5:52 PM
$BCTX
0 replies
Grinchysimon Sep 24, 5:46 PM
$BCTX corrr she’s looking a tad feisty today. Strap in guys and gals
0 replies
BCTX20bMC Sep 24, 5:27 PM
$BCTX who wants to be the last to cover. 🌋
0 replies
Merlintrader Sep 24, 8:29 AM
BriaCell ($BCTX): Seventh DSMB Recommendation to Continue Bria-ABC Phase 3 Free Biotech Catalyst Calendar on Merlintrader. https://www.merlintrader.com/briacell-therapeutics-stock-hub/
0 replies